{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T22:55:00Z","timestamp":1772578500614,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-39142-x","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T04:20:17Z","timestamp":1770610817000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The early impact of bariatric surgery on metabolic dysfunction-associated steatotic liver disease (MASLD) as assessed by fibroscan at 6 months postoperatively"],"prefix":"10.1038","volume":"16","author":[{"given":"Wymin","family":"Sivakumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derbrenn","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayder","family":"Shabana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Crusher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Tuite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catriona","family":"O\u2019Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diarmaid","family":"Houlihan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Stack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colm","family":"O\u2019Boyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"issue":"6","key":"39142_CR1","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 79 (6), 1542\u20131556 (2023).","journal-title":"J. Hepatol."},{"issue":"3","key":"39142_CR2","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1055\/a-1862-9088","volume":"42","author":"M El-Kassas","year":"2022","unstructured":"El-Kassas, M. et al. Nonalcoholic fatty liver disease: Current global burden. Semin Liver Dis. 42 (3), 401\u2013412 (2022).","journal-title":"Semin Liver Dis."},{"issue":"4","key":"39142_CR3","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi, Z. M. et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review. Hepatology 77 (4), 1335\u20131347 (2023).","journal-title":"Hepatology"},{"key":"39142_CR4","doi-asserted-by":"publisher","first-page":"156014","DOI":"10.1016\/j.metabol.2024.156014","volume":"160","author":"A Mantovani","year":"2024","unstructured":"Mantovani, A., Lonardo, A., Stefan, N. & Targher, G. Metabolic dysfunction-associated steatotic liver disease and extrahepatic Gastrointestinal cancers. Metabolism 160, 156014 (2024).","journal-title":"Metabolism"},{"issue":"2","key":"39142_CR5","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1016\/j.jhep.2023.08.003","volume":"80","author":"Q Zhao","year":"2024","unstructured":"Zhao, Q. & Deng, Y. Comparison of mortality outcomes in individuals with MASLD and\/or MAFLD. J. Hepatol. 80 (2), e62\u2013e64 (2024).","journal-title":"J. Hepatol."},{"issue":"3","key":"39142_CR6","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD)","year":"2024","unstructured":"European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD). European association for the study of obesity (EASO). EASL\u2013EASD\u2013EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J. Hepatol. 81 (3), 492\u2013542 (2024).","journal-title":"J. Hepatol."},{"key":"39142_CR7","unstructured":"Food, U. S. & Administration, D. FDA Approves First Treatment for Patients with Liver Scarring Due To Fatty Liver Disease [press release] (FDA, 2024). Mar 14 [cited 2025 Nov 24]."},{"key":"39142_CR8","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison, S. A. et al. A phase 3, randomized, controlled trial of Resmetirom in NASH with liver fibrosis. N Engl. J. Med. 390, 497\u2013509 (2024).","journal-title":"N Engl. J. Med."},{"issue":"21","key":"39142_CR9","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","volume":"392","author":"AJ Sanyal","year":"2025","unstructured":"Sanyal, A. J. et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl. J. Med. 392 (21), 2089\u20132099 (2025).","journal-title":"N Engl. J. Med."},{"issue":"1","key":"39142_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11695-022-06332-1","volume":"33","author":"D Eisenberg","year":"2023","unstructured":"Eisenberg, D. et al. 2022 American society for metabolic and bariatric surgery (ASMBS) and international federation for the surgery of obesity and metabolic disorders (IFSO): Indications for metabolic and bariatric surgery. Obes. Surg. 33 (1), 3\u201314 (2023).","journal-title":"Obes. Surg."},{"issue":"2","key":"39142_CR11","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","volume":"149","author":"E Vilar-Gomez","year":"2015","unstructured":"Vilar-Gomez, E. et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149 (2), 367\u201375e15 (2015).","journal-title":"Gastroenterology"},{"key":"39142_CR12","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.soard.2018.12.002","volume":"15","author":"TK Fakhry","year":"2019","unstructured":"Fakhry, T. K. et al. Bariatric surgery improves nonalcoholic fatty liver disease: A contemporary systematic review and meta-analysis. Surg. Obes. Relat. Dis. 15, 502\u2013511 (2019).","journal-title":"Surg. Obes. Relat. Dis."},{"issue":"11","key":"39142_CR13","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1111\/hepr.13821","volume":"52","author":"Y Nagaoki","year":"2022","unstructured":"Nagaoki, Y. et al. Prevalence of fatty liver and advanced fibrosis by ultrasonography and fibroscan in a general population random sample. Hepatol. Res. 52 (11), 908\u2013918 (2022).","journal-title":"Hepatol. Res."},{"issue":"3","key":"39142_CR14","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1002\/hep.25993","volume":"57","author":"J Boursier","year":"2013","unstructured":"Boursier, J. et al. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology 57 (3), 1182\u20131191 (2013).","journal-title":"Hepatology"},{"key":"39142_CR15","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.cgh.2018.04.043","volume":"17","author":"MS Siddiqui","year":"2019","unstructured":"Siddiqui, M. S. et al. Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 17, 156\u2013163 (2019).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"5","key":"39142_CR16","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1007\/s11695-014-1496-3","volume":"25","author":"JP Sczepaniak","year":"2015","unstructured":"Sczepaniak, J. P., Owens, M. L., Shukla, H., Perlegos, J. & Garner, W. Comparability of weight loss reporting after gastric bypass and sleeve gastrectomy using BOLD data 2008\u20132011. Obes. Surg. 25 (5), 788\u2013795 (2015).","journal-title":"Obes. Surg."},{"issue":"5","key":"39142_CR17","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","volume":"66","author":"T Karlas","year":"2017","unstructured":"Karlas, T. et al. Individual patient data meta-analysis of controlled Attenuation parameter technology for assessing steatosis. J. Hepatol. 66 (5), 1022\u20131030 (2017).","journal-title":"J. Hepatol."},{"key":"39142_CR18","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s11901-017-0368-4","volume":"16","author":"T Hardy","year":"2017","unstructured":"Hardy, T. & McPherson, S. Imaging-based assessment of steatosis, inflammation and fibrosis in NAFLD. Curr. Hepatol. Rep. 16, 298\u2013307 (2017).","journal-title":"Curr. Hepatol. Rep."},{"issue":"4","key":"39142_CR19","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1055\/s-0043-103952","volume":"38","author":"CF Dietrich","year":"2017","unstructured":"Dietrich, C. F. et al. EFSUMB guidelines and recommendations on the clinical use of liver ultrasound elastography: Update 2017 (long version). Ultraschall Med. 38 (4), e16\u201347 (2017).","journal-title":"Ultraschall Med."},{"issue":"1058","key":"39142_CR20","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/postgradmedj-2012-131640","volume":"89","author":"MJ Armstrong","year":"2013","unstructured":"Armstrong, M. J. et al. Operator training requirements and diagnostic accuracy of fibroscan in routine clinical practice. Postgrad. Med. J. 89 (1058), 685\u2013692 (2013).","journal-title":"Postgrad. Med. J."},{"issue":"5","key":"39142_CR21","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1136\/gutjnl-2021-324243","volume":"71","author":"FE M\u00f3zes","year":"2022","unstructured":"M\u00f3zes, F. E. et al. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: An individual patient data meta-analysis. Gut 71 (5), 1006\u20131019 (2022).","journal-title":"Gut"},{"issue":"3","key":"39142_CR22","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1136\/gut.2005.069153","volume":"55","author":"J Foucher","year":"2006","unstructured":"Foucher, J. et al. Diagnosis of cirrhosis by transient elastography (FibroScan): A prospective study. Gut 55 (3), 403\u2013408 (2006).","journal-title":"Gut"},{"issue":"8","key":"39142_CR23","doi-asserted-by":"publisher","first-page":"e3045","DOI":"10.1002\/dmrr.3045","volume":"34","author":"NN Wijayatunga","year":"2018","unstructured":"Wijayatunga, N. N. et al. Roux-en-Y gastric bypass surgery alters serum metabolites and fatty acids in patients with morbid obesity. Diabetes Metab. Res. Rev. 34 (8), e3045 (2018).","journal-title":"Diabetes Metab. Res. Rev."},{"key":"39142_CR24","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s12893-022-01760-3","volume":"22","author":"F Eghbali","year":"2022","unstructured":"Eghbali, F. et al. Predictors for weight loss after Roux-en-Y gastric bypass: The trend and associated factors for weight loss. BMC Surg. 22, 310 (2022).","journal-title":"BMC Surg."},{"issue":"6","key":"39142_CR25","doi-asserted-by":"publisher","first-page":"353","DOI":"10.4174\/astr.2022.102.6.353","volume":"102","author":"KH Kim","year":"2022","unstructured":"Kim, K. H., Kim, Y., Seo, K. I. & Seo, K. W. Short-term outcome of bariatric surgery on nonalcoholic fatty liver disease: A Korean perspective. Ann. Surg. Treat. Res. 102 (6), 353\u2013359 (2022).","journal-title":"Ann. Surg. Treat. Res."},{"key":"39142_CR26","doi-asserted-by":"crossref","unstructured":"Cossiga, V. et al. The early impact of bariatric surgery on liver fibrosis and steatosis in MASLD patients. Dig. Liver Dis. (2025).","DOI":"10.1016\/j.dld.2025.01.021"},{"issue":"4","key":"39142_CR27","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","volume":"159","author":"G Lassailly","year":"2020","unstructured":"Lassailly, G. et al. Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis. Gastroenterology 159 (4), 1290\u20131301e5 (2020).","journal-title":"Gastroenterology"},{"issue":"1","key":"39142_CR28","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12876-019-1002-4","volume":"19","author":"L Tanajewski","year":"2019","unstructured":"Tanajewski, L. et al. Economic evaluation of non-invasive liver fibrosis tests for treatment decisions in patients with chronic liver disease. BMC Gastroenterol. 19 (1), 98 (2019).","journal-title":"BMC Gastroenterol."},{"issue":"7","key":"39142_CR29","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJM200102153440706","volume":"344","author":"AA Bravo","year":"2001","unstructured":"Bravo, A. A., Sheth, S. G. & Chopra, S. Liver biopsy. N Engl. J. Med. 344 (7), 495\u2013500 (2001).","journal-title":"N Engl. J. Med."},{"issue":"5","key":"39142_CR30","first-page":"1557","volume":"139","author":"J West","year":"2010","unstructured":"West, J. et al. Death within 7 days related to percutaneous liver biopsy is at most 1 in 10,000 biopsies. Gastroenterology 139 (5), 1557\u20131558 (2010).","journal-title":"Gastroenterology"},{"issue":"6","key":"39142_CR31","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","volume":"156","author":"PJ Eddowes","year":"2019","unstructured":"Eddowes, P. J. et al. Accuracy of fibroscan controlled Attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 156 (6), 1717\u20131730 (2019).","journal-title":"Gastroenterology"},{"issue":"5","key":"39142_CR32","doi-asserted-by":"publisher","first-page":"466","DOI":"10.5152\/tjg.2021.20498","volume":"32","author":"A Avcu","year":"2021","unstructured":"Avcu, A., Kaya, E. & Yilmaz, Y. Feasibility of fibroscan in assessment of hepatic steatosis and fibrosis in obese patients. Turk. J. Gastroenterol. 32 (5), 466\u2013472 (2021).","journal-title":"Turk. J. Gastroenterol."},{"issue":"3","key":"39142_CR33","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1007\/s11695-025-07733-8","volume":"35","author":"Y Nie","year":"2025","unstructured":"Nie, Y., Zhang, Y., Liu, B. & Meng, H. Glucagon-like peptide-1 receptor agonists for the treatment of suboptimal initial clinical response and weight gain recurrence after bariatric surgery: A systematic review and meta-analysis. Obes. Surg. 35 (3), 808\u2013822 (2025).","journal-title":"Obes. Surg."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39142-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39142-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39142-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T22:02:32Z","timestamp":1772575352000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39142-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["39142"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-39142-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"assertion":[{"value":"18 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethical approval for this study was granted by the Cork Research Ethics Committee (CREC), Cork Teaching Hospitals, approved by the committee chairperson Professor Brendan Buckley. Ethical approval was also granted by the Bon Secours Hospital Clinical Ethics Committee Research Sub-Committee Sciences, approved by ethics consultant Professor David Smith and chairperson Ms. Mary Dunne. Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"8002"}}